This company listing is no longer active
Resumen de acción EPZM
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Competidores de Epizyme, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.47 |
| 52 Week High | US$5.80 |
| 52 Week Low | US$0.41 |
| Beta | -0.42 |
| 1 Month Change | -0.68% |
| 3 Month Change | 182.37% |
| 1 Year Change | -72.78% |
| 3 Year Change | -89.29% |
| 5 Year Change | -89.54% |
| Change since IPO | -93.61% |
Noticias y actualizaciones recientes
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16
Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme gains as peer Constellation attracts sizable premium from MorphoSys
Jun 02Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16
Epizyme says Boehringer terminates collaboration agreement
Dec 24Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Epizyme Q3 2020 Earnings Preview
Nov 05Rentabilidad de los accionistas
| EPZM | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -3.3% | 4.8% | 0.7% |
| 1Y | -72.8% | 2.8% | 23.9% |
Rentabilidad vs. Industria: EPZM underperformed the US Biotechs industry which returned -23% over the past year.
Rentabilidad vs. Mercado: EPZM underperformed the US Market which returned -11.7% over the past year.
Volatilidad de los precios
| EPZM volatility | |
|---|---|
| EPZM Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: EPZM's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: EPZM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 250 | Grant Bogle | www.epizyme.com |
Resumen de fundamentos de Epizyme, Inc.
| Estadísticas fundamentales de EPZM | |
|---|---|
| Capitalización bursátil | US$247.50m |
| Beneficios(TTM) | -US$207.73m |
| Ingresos (TTM) | US$53.01m |
4.7x
Ratio precio-ventas (PS)-1.2x
Ratio precio-beneficio (PE)¿Está EPZM sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de EPZM | |
|---|---|
| Ingresos | US$53.01m |
| Coste de los ingresos | US$10.79m |
| Beneficio bruto | US$42.22m |
| Otros gastos | US$249.95m |
| Beneficios | -US$207.73m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.23 |
| Margen bruto | 79.64% |
| Margen de beneficio neto | -391.88% |
| Ratio deuda/patrimonio | -1,148.4% |
¿Cómo se ha desempeñado EPZM a largo plazo?
Ver rendimiento histórico y comparativa